Cannabinoid-NAD+ Precursor Formulation for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory cannabinoid formulations lack efficacy and are not well-suited for traditional drug delivery methods, despite the known benefits of cannabinoids like CBD for inflammation reduction.
Innovation Solution
A combination formulation of CBD with NAD+ precursors, such as nicotinamide adenine dinucleotide (NAD+) precursors, in specific ratios, which can be administered via various routes, including oral, topical, and pulmonary, to reduce inflammation by decreasing the secretion of inflammatory cytokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoid formulations are used for anti-inflammatory treatment, then some anti-inflammatory effect is achieved, but the efficacy is insufficient and they are not well-suited for traditional drug delivery methods
Solution Approach 1:
The patent combines cannabinoids with NAD+ precursors (such as nicotinamide, nicotinic acid, or tryptophan) in a single formulation to achieve synergistic anti-inflammatory effects. This merging of two active components addresses the insufficient efficacy of cannabinoid-only formulations while maintaining compatibility with traditional drug delivery methods through established formulation techniques
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both cannabinoid compounds and NAD+ precursor compounds. This composite approach leverages the complementary mechanisms of action between cannabinoids (which modulate the endocannabinoid system) and NAD+ precursors (which support cellular energy metabolism and reduce oxidative stress), thereby achieving enhanced anti-inflammatory efficacy suitable for traditional delivery routes
2Reliability
If higher doses of cannabinoids are used to improve anti-inflammatory efficacy, then the therapeutic effect increases, but the formulation becomes less suitable for traditional drug delivery methods
Solution Approach 1:
By combining cannabinoids with NAD+ precursors, the patent achieves enhanced anti-inflammatory efficacy at lower effective doses, reducing the need for high-dose cannabinoid formulations that would be difficult to deliver through traditional methods. The synergistic interaction allows for lower individual component doses while maintaining or improving therapeutic effect
Solution Approach 2:
The invention optimizes the formulation by establishing specific concentration ranges and ratios between cannabinoids and NAD+ precursors. This parameter optimization ensures effective anti-inflammatory activity while maintaining compatibility with traditional drug delivery methods, avoiding the complexity associated with high-dose formulations
Data Source
AI summary
The present invention describes cannabinoid formulations that combine cannabinoids, such as CBD, with other active agents within the NAD+ precursor class of compounds which, in combination, provide synergistic anti-inflammatory effects. These preparations are capable of increasing anti-inflammatory effects when compared to each individual compound, and are further capable of delivery through a variety of administration routes.